NIH Archives -

FDA clears Gilead’s Veklury for COVID outpatients

Phil Taylor antiviral, coronavirus, COVID-19, fda, Gilead Sciences, NIH, Veklury 0 Comment

The FDA has extended the emergency use authorisation for Gilead Sciences’ antiviral Veklury to include non-hospitalised patients with

FDA clears Gilead’s Veklury for COVID outpatients

https://pharmaphorum.com/news/fda-clears-gileads-veklury-for-covid-outpatients/

Market Access/ News/ News

Moderna squares off with US government over COVID jab patent

Phil Taylor access, coronavirus, COVID-19, COVID-19 vaccine, Intellectual property, Moderna, NIH 0 Comment

After being hailed as a triumph of public-private drug development, Moderna’s partnership with the US government on its

Moderna squares off with US government over COVID jab patent

https://pharmaphorum.com/news/moderna-squares-off-with-us-over-covid-shot-patents/

News/ News/ R&D

More malaria hope as NIH antibody protects against infection

Phil Taylor antibody, infectious disease, Malaria, NIAID, NIH, parasitology, R&D 0 Comment

A single dose of a monoclonal antibody developed by scientists at the US National Institutes of Health (NIH)

More malaria hope as NIH antibody protects against infection

https://pharmaphorum.com/news/more-malaria-hope-as-antibody-protects-against-infection/

Digital/ News/ News

NIH digital tool aims to boost enrolment into Alzheimer’s studies

Phil Taylor Alzheimer's disease, clinical trials, digital, digital health, NIH, patient retention, recruitment 0 Comment

With a string of new drugs for Alzheimer’s disease making their way through late-stage clinical testing, the demand

NIH digital tool aims to boost enrolment into Alzheimer’s studies

https://pharmaphorum.com/news/nih-digital-tool-aims-to-boost-enrolment-into-alzheimers-studies/

News/ News/ Patients

NIH abandons convalescent plasma trial in mild COVID

Phil Taylor convalescent plasma, coronavirus, COVID-19, immunology, NIH 0 Comment

Another trial of convalescent plasma in people with COVID-19 has missed the mark, this time in mild to

NIH abandons convalescent plasma trial in mild COVID

https://pharmaphorum.com/news/nih-abandons-convalescent-plasma-trial-in-mild-covid/

News/ News/ R&D

US experts stress over safety of AZ’s COVID-19 vaccine

Richard Staines AstraZeneca, coroanvirus, COVID-19, NIH, vaccine 0 Comment

US medical experts are reportedly concerned that a neurological side effect picked up in AstraZeneca’s closely-watched COVID-19 vaccine

US experts stress over safety of AZ’s COVID-19 vaccine

https://pharmaphorum.com/news/us-experts-stress-over-safety-of-azs-covid-19-vaccine/

News/ News/ R&D

US trials of Gilead’s remdesivir begin against COVID-19 coronavirus

Richard Staines antivirals, coronavirus, COVID-19, Gilead, infectious diseases, NIH, R&D, vaccines 0 Comment

The first US trial of Gilead’s unapproved antiviral remdesivir has officially begun against the novel coronavirus disease COVID-19.

US trials of Gilead’s remdesivir begin against COVID-19 coronavirus

https://pharmaphorum.com/news/us-trials-of-gileads-remdesivir-begin-against-covid-19-coronavirus/

News/ R&D

Trump’s budget cuts will be disastrous for healthcare and patients, say cell therapy leaders

Andrew McConaghie Donald Trump, International Society of Cellular Therapy, NIH 0 Comment

Following President Trump’s announcement of massive cuts to the National Institutes of Health funding last week, science leaders

Trump’s budget cuts will be disastrous for healthcare and patients, say cell therapy leaders

https://pharmaphorum.com/news/trumps-budget-cuts-will-disastrous-healthcare-patients-say-cell-therapy-leaders/

Clinical/ News/ R&D/ US

Dream of artificial pancreas closer with NIH trials

Marco Ricci artificial pancreas, closed loop system, diabtes, NIH, type 1 diabetes 0 Comment

Four international trials will speed development of technology

Dream of artificial pancreas closer with NIH trials

https://pharmaphorum.com/news/dream-of-artificial-pancreas-closer-with-nih-trials/

Trending

NIH

Login